Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
Nascent Biotech, Inc. (OTCMKTS:NBIO) is a clinical-stage biotechnology company formed in 2014. The company focuses on developing pritumumab, a human monoclonal antibody designed to target brain and pancreatic cancers. With a team of leading scientists specializing in monoclonal antibodies and cytokine treatments, Nascent aims to modulate the human body's immune response through immunotherapy. The combination of monoclonal antibodies and cytokines enhances therapeutic effectiveness against various diseases. Nascent Biotech is pioneering innovative cancer treatments that prioritize patient outcomes and shareholder value.
Rhea-AI Summary
Nascent Biotech, Inc. prepares for a pivotal Phase II research by embarking on a fresh manufacturing run to ensure maximum potency of Pritumumab supplies for the upcoming clinical trial. The Company aims to prioritize patient outcomes and long-term shareholder value by taking careful steps in the trial process. The Phase I trial showed promising safety results, especially in treating Glioblastoma, with no dose-related toxicities. The Phase II trial will focus on clinical outcomes and efficient patient recruitment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.22%
Tags
-
Rhea-AI Summary
Nascent Biotech collaborates with HypoSpray Pharma to develop alternative delivery mechanism for cancer treatment, aiming to improve patient care and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
Rhea-AI Summary
Nascent Biotech, Inc. (NBIO) announced a research collaboration agreement with Manhattan BioSolutions, Inc. to explore antibody-drug conjugates using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element. PTB is a natural human antibody that targets extracellular vimentin, a protein linked to cancer growth. It has demonstrated safety and preliminary efficacy in Phase I study in glioblastoma patients. Nascent has FDA clearance to begin Phase II clinical trials for brain cancer. The collaboration aims to prioritize promising ADC candidates for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.41%
Tags
Rhea-AI Summary
Nascent Biotech, Inc. (NBIO) analysts suggest value at $0.60 to $2.84 per share. The company is a clinical-stage biotechnology company developing monoclonal antibodies focused on treating various cancers. Nascent was featured in an independent research report by Marble Arch Research, highlighting the investment potential of their common stock. The report underscores the company's conviction that their stock is undervalued. CEO Sean Carrick remarks on the potential breakthrough therapy of Pritumumab (PTB) in the $1.8 billion underserved brain cancer market, demonstrating safety, efficacy, and the ability to breach the blood-brain barrier to attack brain cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
-
News
Rhea-AI Summary
Nascent Biotech, Inc. (OTCQB:NBIO) has announced the completion of payment of all outstanding variable convertible debt obligations, demonstrating their commitment to prioritize shareholder interests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
-
Rhea-AI Summary
Nascent Biotech, Inc. (NBIO) has been issued a 'Method-of-Use' patent from the Japanese Patent Office for its primary asset, Pritumumab (PTB), related to PTB's capacity to cross through the Blood-Brain Barrier. The patent approval recognizes PTB's ability to act as a monotherapy and as a conjugate, bringing other therapies across the BBB. Nascent's senior management sees this as a significant event elevating the Company's value proposition and strengthening its intellectual property position internationally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
Rhea-AI Summary
Nascent Biotech cleared by FDA for Phase II clinical trials for brain cancer with its therapeutic antibody Pritumumab (PTB).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.6%
Tags
-
Rhea-AI Summary
Nascent Biotech presented their Phase I Clinical Data at the American Society of Clinical Oncology (ASCO) meeting. The data showed the drug to be very safe at 5 ascending dose cohorts and demonstrated bioactivity in several patients. The therapeutic antibody Pritumumab (PTB) targets cell surface Vimentin and recruits the immune system to eliminate cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
FAQ
When was Nascent Biotech, Inc. established?
Nascent Biotech, Inc. was formed in March 2014.
What is the focus of Nascent Biotech, Inc.'s research and development?
The company concentrates on developing pritumumab, a human monoclonal antibody intended for brain and pancreatic cancer treatments.
What is Nascent Biotech, Inc.'s clinical premise for treating diseases?
Nascent Biotech believes in modulating the human body's immune response through immunotherapy using monoclonal antibodies and cytokines.
How does Nascent Biotech, Inc. distinguish itself in the biotechnology sector?
The company combines scientific expertise in monoclonal antibodies and cytokine treatments to maximize therapeutic effectiveness against a range of diseases.
What are Nascent Biotech, Inc.'s primary areas of focus for disease treatment?
Nascent Biotech is primarily focused on developing treatments for brain and pancreatic cancers, addressing unmet clinical needs.
Nascent Biotech, Inc.
OTC:NBIO
NBIO Rankings
NBIO Stock Data
15.09M
93.95M
40%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
North Palm Beach